Sahajanand Medical Technologies IPO Price: ₹327 to ₹344 per share
IPO Dates: 15 to 19 Oct, 2026
Company Overview
Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention.
Product Portfolio
The Company’s product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.
Research and Development
The Company focuses on research and development, precision manufacturing and clinically supported product innovation. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India.
Manufacturing Facilities
The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand.
Global Presence
The Company’s products were marketed in 77 countries in Fiscal 2026 through direct, hybrid and distributor-led models, with an established market presence in India, Europe and other international markets.
Financial Performance
The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024.
Workforce
As of June 30, 2026, the Company had 1,605 full-time employees, 31 consultants and 707 contract-based employees.
Competitive Strengths
- Extensive global sales and marketing network.
- Strong research and development capabilities.
- Diversified and integrated manufacturing facilities.
- Leadership in India and key international markets.
- Proven M&A and strategic collaboration capabilities.
- Technologically advanced medical devices in high-barrier segments.
- Experienced leadership team backed by reputed institutional investors.
Bidding Starts In
Sahajanand Medical Technologies Limited IPO Specifics:
| IPO Date | 15 to 19 Oct, 2026 |
| Listing Date | Fri, Oct 23, 2026 |
| Face Value | ₹1 per share |
| Price Band | ₹327 to ₹344 |
| Lot Size | 43 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,38,22,116 shares (agg. up to ₹475 Cr) |
| Offer for Sale | 1,38,22,116 shares of ₹1 (agg. up to ₹475 Cr) |
| Share Holding Pre Issue | 10,16,46,778 shares |
| Share Holding Post Issue | 10,16,46,778 shares |
Sahajanand Medical Technologies Limited IPO Timetable (Important Dates)
| Event | Date |
|---|---|
| IPO Open | Thu, Oct 15, 2026 |
| IPO Close | Mon, Oct 19, 2026 |
| Allotment | Wed, Oct 21, 2026 |
| Refund | Thu, Oct 22, 2026 |
| Credit of Shares | Thu, Oct 22, 2026 |
| Listing | Fri, Oct 23, 2026 |
Sahajanand Medical Technologies Limited IPO Lot Size
Bidders have the opportunity to bid for a minimum of 43 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 43 | ₹14,792 |
| Retail (Max) | 13 | 559 | ₹1,92,296 |
| S-HNI (Min) | 14 | 602 | ₹2,07,088 |
| S-HNI (Max) | 67 | 2881 | ₹9,91,064 |
| B-HNI (Min) | 68 | 2924 | ₹10,05,856 |
Sahajanand Medical Technologies Limited IPO Reservation
| Investor Category | Shares |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
Sahajanand Medical Technologies Limited IPO Financial Information
| Particulars (₹ Cr) | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| NET Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves and Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
Key Performance Indicator-Sahajanand Medical Technologies Limited IPO
| KPI | Jun 30, 2026 | Mar 31, 2026 |
|---|---|---|
| ROE | 2.07% | 10.35% |
| ROCE | 3.16% | 11.57% |
| Debt/Equity | 0.33 | 0.27 |
| RoNW | 2.31% | 10.60% |
| PAT Margin | 4.29% | 5.71% |
| EBITDA Margin | 13.81% | 14.10% |
| NAV | 64.35 | 62.76 |
| P/B (x) | 5.48 |
| Valuation Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 6.80 | 5.94 |
| P/E (x) | 50.59 | 57.91 |
| Market Cap at Offer Price | ₹3,496.65 Cr. | ₹3,496.65 Cr. |
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
Sahajanand Medical Technologies Limited IPO RHP
Kaashika is a social media strategist and financial content creator at Lakshmishree. She specialises in simplifying complex IPO and stock market concepts into clear, easy-to-understand content. Having created over 500+ pieces of financial content across reels, blogs, website posts and digital creatives, Kaashika helps audiences connect with the world of finance in a more accessible and engaging way.
